06.03.2025 |
Management Team, News

BioStock interview with CEO John Glasspool on VMX-C001 at BioCapital Europe

Related items

20.08.2026

News

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgery
First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking…
Read more

24.02.2026

News, Scientific publications

VarmX announces publication of sensitive coagulation assays to assess restoration of coagulation using VMX-C001 in the presence of Factor Xa inhibitors
Key Highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for…
Read more